We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis.
- Authors
Yang, Hongcheng; Shao, Ruoyang; Huang, Hongxin; Wang, Xinlong; Rong, Zhili; Lin, Ying
- Abstract
The use of immunotherapy has achieved great advances in the treatment of cancer. Macrophages play a pivotal role in the immune defense system, serving both as phagocytes (removal of pathogens and cancer cells) and as antigen‐presenting cells (activation of T cells). However, research regarding tumor immunotherapy is mainly focused on the adaptive immune system. The usefulness of innate immune cells (eg, macrophages) in the treatment of cancer has not been extensively investigated. Recent advances in synthetic biology and the increasing understanding of the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPɑ) axis may provide new opportunities for the clinical application of engineered macrophages. The CD47/SIRPɑ axis is a major known pathway, repressing phagocytosis and activation of macrophages. In this article, we summarize the currently available evidence regarding the CD47/SIRPɑ axis, and immunotherapies based on blockage. In addition, we propose cell therapy strategies based on macrophage engineering.
- Subjects
CANCER cells; MACROPHAGES; IMMUNE system; MACROPHAGE activation; PHAGOCYTES
- Publication
Cancer Medicine, 2019, Vol 8, Issue 9, p4245
- ISSN
2045-7634
- Publication type
Article
- DOI
10.1002/cam4.2332